Novel agents for the treatment of Hodgkin lymphoma

Expert Review of Hematology
Komal Dumaswala, Amitkumar Mehta

Abstract

Hodgkin lymphoma (HL) is highly curable lymphoma with combined multiagent chemotherapy with or without radiation. In spite of higher cure rates, approximately 20-30% cases will be either refractory or relapse after first line therapy. For relapse/refractory HL, salvage chemotherapy followed by autologous stem cell transplant remains the standard of care. Because of early and late toxicities of multiagent chemotherapy, there are ongoing efforts to find less toxic therapies to treat HL. Brentuximab vedotin is an antibody drug conjugate targeting CD30 with high response rates in HL. In the last decade, immune oncology has changed the treatment paradigm of cancers. Biologically, Reed-Sternberg cells evade immune system by exploiting checkpoint pathways. Inhibition of checkpoint pathway has shown promising activity in HL. Recently, phosphatidyl-inositide 3 kinase inhibitors and Janus kinase inhibitors have shown impressive responses in HL. In this article, we discuss novel agents in HL.

References

Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R ColwillA Keating
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M G PfreundschuhR Kuse
May 31, 2002·Blood·Brian F Skinnider, Tak W Mak
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Graça M DoresLois B Travis
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Berthe M P AlemanFlora E van Leeuwen
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertUNKNOWN German Hodgkin's Study Group
Apr 12, 2006·The Journal of Experimental Medicine·Mary E KeirArlene H Sharpe
Nov 23, 2006·Blood·Berthe M P AlemanFlora E van Leeuwen
May 27, 2008·Nature Reviews. Immunology·Weiping Zou, Lieping Chen
Dec 17, 2008·Nature Reviews. Cancer·Ralf Küppers
Nov 5, 2010·The New England Journal of Medicine·Anas YounesAndres Forero-Torres
Jan 26, 2011·Blood·John KuruvillaMichael Crump
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian SteidlRandy D Gascoyne
Jun 2, 2011·Nature Reviews. Drug Discovery·Vernon K SondakPeter Kirkpatrick
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony J SwerdlowDavid C Linch
Nov 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michelle A FanaleNancy L Bartlett
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marleen A E van der KaaijHanneke C Kluin-Nelemans
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesAndreas Engert
Sep 11, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Angelo de ClaroRichard Pazdur
Nov 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karolin BehringerPeter Borchmann
Jan 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael Zach KoontzRanjana H Advani
Apr 23, 2013·Therapeutic Advances in Hematology·Christos Vaklavas, Andres Forero-Torres
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Apr 29, 2015·JAMA Internal Medicine·Frederika A van NimwegenFlora E van Leeuwen
May 13, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·Richard T HoppeUNKNOWN National comprehensive cancer network

❮ Previous
Next ❯

Citations

May 20, 2017·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Jinjun ChengJohn Kim Choi
Jul 16, 2019·Leukemia & Lymphoma·Isacco FerrariniFabrizio Vinante

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Hirokazu Nagai
Annals of Oncology : Official Journal of the European Society for Medical Oncology
A Stathis, Anas Younes
Current Hematologic Malignancy Reports
Francesca Montanari, Catherine S M Diefenbach
Journal of the National Comprehensive Cancer Network : JNCCN
Shira Dinner, Ranjana Advani
© 2021 Meta ULC. All rights reserved